← Eichor
Study identifier: NCT06548971 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)

Condition: Acute Ischemic Stroke · Cerebral Infarction  ·  Sponsor: Capital Medical University

PhasePhase 3
Planned participants1184
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis. Currently, guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding. The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear. The study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis, early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrh…

This description comes directly from the study's public registry record.

Talk to the study team

XunMing Ji, MD, PD  ·  010-8319-9439  ·  jixm@ccmu.edu.cn

Wenbo Zhao, MD, PD  ·  010-8319-9048  ·  zhaowb@xwh.ccmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (71)

The Third The People's Hospital Of BengbuBengbu, Anhui, ChinaRecruiting
Suzhou municipal hospitalSuzhou, Anhui, ChinaRecruiting
Xuanwu Hospital, Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Aerospace central hospitalHaidian, Beijing Municipality, ChinaRecruiting
Beijing Pinggu District HospitalPinggu, Beijing Municipality, ChinaRecruiting
Beijing Luhe Hospital affiliated to Capital Medical UniversityTongzhou, Beijing Municipality, ChinaRecruiting
Fujian university affiliated provincial hospitalFuzhou, Fujian, ChinaRecruiting
The First Affiliated Hospital Of Xiamen UniversityXiamen, Fujian, ChinaRecruiting
Xiamen Xinglin hospitalXiamen, Fujian, ChinaNot Yet Recruiting
Zhangzhou Hospital of Fujian ProvinceZhangzhou, Fujian, ChinaRecruiting
Brain Hospital Affiliated to Guangzhou Medical UniversityGuangzhou, Guangdong, ChinaNot Yet Recruiting
Guigang people's hospitalvGuigang, Guangxi, ChinaRecruiting

+ 59 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06548971